Pfizer Inc. $PFE Shares Acquired by Sterling Investment Advisors Ltd.

Sterling Investment Advisors Ltd. increased its position in Pfizer Inc. (NYSE:PFE) by 27.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 124,752 shares of the biopharmaceutical company’s stock after buying an additional 27,192 shares during the quarter. Sterling Investment Advisors Ltd.’s holdings in Pfizer were worth $3,503,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Penn Davis Mcfarland Inc. boosted its position in Pfizer by 50.9% during the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after purchasing an additional 57,777 shares during the period. Danske Bank A S purchased a new position in Pfizer in the third quarter valued at about $81,298,000. Vanguard Group Inc. raised its position in Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. KBC Group NV lifted its stake in shares of Pfizer by 8.3% during the fourth quarter. KBC Group NV now owns 9,193,713 shares of the biopharmaceutical company’s stock worth $228,924,000 after purchasing an additional 706,426 shares in the last quarter. Finally, Pensionfund Sabic purchased a new stake in shares of Pfizer in the fourth quarter worth about $1,863,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 1.0%

NYSE:PFE opened at $24.24 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The business’s 50-day simple moving average is $25.28 and its 200 day simple moving average is $26.18. The stock has a market cap of $138.17 billion, a price-to-earnings ratio of 18.51 and a beta of 0.35.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same quarter last year, the firm earned $0.92 EPS. Pfizer’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent research reports. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. CICC Research began coverage on Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 9th. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Finally, HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and reduced their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.50.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst coverage remains supportive, even after some modest price-target cuts. BMO kept an outperform rating and Guggenheim maintained a buy, suggesting Wall Street still sees upside from current levels. Benzinga analyst update
• Positive Sentiment: Pfizer’s oncology franchise is in focus ahead of Q2 results, with growth from key cancer drugs, biosimilars, and pipeline updates potentially helping offset declines in older medicines. Zacks oncology outlook
• Positive Sentiment: Investors are also encouraged by the long-term case for Pfizer’s Seagen integration, which some analysts argue could improve oncology growth and create durable value versus peers like Amgen. 247WallSt Pfizer vs. Amgen
• Neutral Sentiment: Pfizer’s dividend yield remains unusually high at about 7.1%, which may attract income investors, but it also raises questions about whether the payout reflects slower growth expectations. Motley Fool dividend article
• Negative Sentiment: Near-term earnings expectations are soft, with Wall Street looking for a double-digit decline in profit in the next quarterly report, reinforcing concerns about pressure on Pfizer’s core business. Barchart earnings preview
• Negative Sentiment: Drug-pricing headlines tied to the Trump administration are adding policy uncertainty across big pharma, including Pfizer, even though pipeline strength may ultimately matter more. Motley Fool drug-pricing article

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.